百花医药 2025 年第二次临时股东会法律意见书 新疆星河井然律师事务所 新疆星河井然律师事务所 关于新疆百花村医药集团股份有限公司 2025年第二次临时股东会的 律师见证法律意见书 星河证股字[2025]第007号 致:新疆百花村医药集团股份有限公司 新疆星河井然律师事务所(以下简称"本所")接受新疆百花村医药 集团股份有限公司(以下简称"公司")的委托,指派本所律师出席公司 2025年第二次临时股东会(以下简称"股东会"或"会议"),并根据《中 华人民共和国公司法》(以下简称"公司法")、《中华人民共和国证券 法》《上市公司股东会规则》等现行法律、法规、规范性文件和《新疆百 花村医药集团股份有限公司》(以下简称"公司章程")的有关规定出具 本法律意见书。 关于本法律意见书,本所及本所律师谨作如下声明: (1) 本所及本所律师本次所发表的法律意见,仅依据本法律意见书出 具日以前已经发生的或者存在的事实并基于本所律师对有关法律、法规和 规范性文件的理解而形成。在本法律意见书中,本所及本所律师仅就本次 会议的召集和召开程序、召集人和出席人员的资格、表决程序以及表决结 果进行核查和见证并发表法律意见,不对本次会议 ...

新疆百花村医药集团股份有限公司 证券代码：600721 证券简称：百花医药 公告编号：2025-042 新疆百花村医药集团股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 288 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 118,179,298 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 30.7320 | | 份总数的比例（%） | | (四) 本次股东会的召集和召开、表决方式符合《公司法》《公司章程》等法 律、法规及规范性文件的规定。本次会议采取现场加网络投票方式，公司董事长 郑彩红女士主持会议。 一、 会议召开和出席情况 (一) 股东会召开的时间：2025 年 11 月 12 日 (二) 股东会召开的地点：新疆百花村医药集团股份有限公司 22 楼会议室 ...

Core Viewpoint - The company has approved a plan to use its reserves to cover accumulated losses, indicating a strategic move to stabilize its financial position [1] Financial Summary - As of the end of 2024, the company's accumulated undistributed profits stand at -1.911 billion yuan, indicating significant financial challenges [1] - The year-end balance of surplus reserves is 5.0303 million yuan, while the capital reserve balance is 2.260 billion yuan [1] - The company plans to utilize 5.0303 million yuan from surplus reserves and 1.910 billion yuan from capital reserves, totaling 1.911 billion yuan, to offset the accumulated losses [1] Creditor Notification - The company has notified creditors that they can request debt repayment or provide guarantees within a specified timeframe [1] - The notification includes details on the application process, location, and contact persons for creditors [1]

Core Viewpoint - Baihua Pharmaceutical (600721.SH) announced plans to use a total of 1.91 billion yuan from its surplus reserve and capital reserve to cover losses, primarily due to goodwill impairment from a previous major asset restructuring [1] Group 1: Financial Actions - The company will hold a board and shareholder meeting on October 27, 2025, to review the proposal for using the surplus and capital reserves [1] - The total amount allocated for loss compensation is 1.91 billion yuan [1] Group 2: Reasons for Losses - The negative retained earnings of the parent company are mainly attributed to the impact of goodwill impairment from the previous major asset restructuring [1] Group 3: Creditor Notification - The company has notified creditors that they can request debt repayment or corresponding guarantees within 30 days from the receipt of the notice or 45 days from the announcement disclosure [1]

Core Points - Baihua Pharmaceutical (600721) closed at 8.96 yuan on November 7, 2025, down 0.33% from 8.99 yuan the previous week [1] - The company's total market capitalization is 3.446 billion yuan, ranking 45th out of 50 in the medical services sector and 4303rd out of 5166 in the A-share market [1] Company Announcements - Baihua Pharmaceutical plans to use surplus reserves of 5,030,274.41 yuan and capital reserves of 1,905,507,702.14 yuan to offset accumulated losses [1] - As of December 31, 2024, the parent company's accumulated undistributed profits stand at -1,910,537,976.55 yuan, with surplus reserves of 5,030,274.41 yuan and capital reserves of 2,260,280,858.86 yuan [1] - The total amount to be used for loss offsetting is 1,910,537,976.55 yuan, which will bring undistributed profits to zero [1] - The plan aims to improve the financial situation, enable profit distribution, and enhance investor return capabilities [1] - This proposal has been submitted for review at the second extraordinary general meeting of shareholders in 2025 [1]

Summary of Key Points Core Viewpoint - Baohua Pharmaceutical (600721) is taking measures to improve its financial situation by utilizing its surplus reserves to offset accumulated losses, which is aimed at enhancing its ability to distribute profits and increase investor returns [1][3]. Trading Information - On November 5, Baohua Pharmaceutical closed at 8.97 yuan, with a slight increase of 0.22%. The turnover rate was 2.24%, with a trading volume of 86,200 shares and a total transaction amount of 76.93 million yuan [1]. - On the same day, the net outflow of main funds was 4.57 million yuan, accounting for 5.94% of the total transaction amount. Retail investors saw a net inflow of 5.99 million yuan, representing 7.79% of the total transaction amount [1][3]. Company Announcement - Baohua Pharmaceutical plans to use its surplus reserves to cover losses. As of December 31, 2024, the company's accumulated undistributed profits amounted to -1,910,537,976.55 yuan. The company intends to use 5,030,274.41 yuan from surplus reserves and 1,905,507,702.14 yuan from capital reserves, totaling 1,910,537,976.55 yuan, to offset these losses [1]. - Following this plan, the surplus reserves will be reduced to 0 yuan, and the capital reserves will decrease to 354,773,156.72 yuan, with undistributed profits also reaching 0 yuan. This proposal has been submitted for review at the second extraordinary shareholders' meeting in 2025 [1].

Group 1 - The core point of the article is that Xinjiang Baihua Village Pharmaceutical Group Co., Ltd. plans to use its surplus reserves to offset accumulated losses, as detailed in the announcement for the 2025 second extraordinary general meeting of shareholders [1] - As of December 31, 2024, the parent company's accumulated undistributed profits stand at -1,910,537,976.55 yuan, while the surplus reserve balance is 5,030,274.41 yuan and the capital reserve balance is 2,260,280,858.86 yuan [1] - The company intends to use 5,030,274.41 yuan from the surplus reserve and 1,905,507,702.14 yuan from the capital reserve, totaling 1,910,537,976.55 yuan, to offset the accumulated losses, with the aim of bringing the negative undistributed profits to zero [1] Group 2 - Following the implementation of this plan, the surplus reserve will be reduced to 0 yuan, the capital reserve will decrease to 354,773,156.72 yuan, and the undistributed profits will also be adjusted to 0 yuan [1] - The source of the capital reserve used for loss offsetting comes from the capital premium formed by shareholders' equity contributions, which has no specific restrictions [1] - The proposal has been submitted for review at the 2025 second extraordinary general meeting of shareholders [1]

新疆百花村医药集团股份有限公司 新疆百花村医药集团股份有限公司 新疆百花村医药集团股份有限公司 2025 年第二次临时股东会议程 （2025 年 11 月 12 日） 新疆百花村医药集团股份有限公司 2025 年第二次临时股东会会议资料 2025 年 11 月 12 日 新疆百花村医药集团股份有限公司 目 录 | 议案：公司关于使用公积金弥补亏损的议案 | 3 | | --- | --- | | 新疆百花村医药集团股份有限公司 2025 | 年第二次临时股东会议程 2 | 1 / 4 | 序 号 | 事项 | | --- | --- | | 宣布公司 | 年第二次临时股东会正式开始 2025 | | 一 | 介绍会议出席情况 | | 二 | 推选计票人及监票人 | | 三 | 宣读并审议议案 | | 1 | 公司关于使用公积金弥补亏损的议案 | | 四 | 与会人员对上述议案进行讨论 | | 五 | 出席会议的股东及股东代理人投票表决 | | 六 | 计票人宣布会议表决结果 | | 七 | 宣读现场会议决议 | | 八 | 见证律师宣读法律意见书 | | 九 | 参会人员在会议决议、会议记录上签字 | | 十 ...

新疆百花村医药集团股份有限公司 证券代码：600721 证券简称：百花医药 公告编号：2025-041 新疆百花村医药集团股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 11 月 10 日（星期一）13:00-14:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 11 月 3 日（星期一）至 11 月 7 日（星期五）16:00 前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 bhc@xjbhc.org 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 新疆百花村医药集团股份有限公司（以下简称"公司"）已于 2025 年 10 月 28 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 ...

Group 1 - The core viewpoint of the news is that the Artemisinin concept sector experienced a slight increase of 0.40%, ranking 9th among concept sectors in terms of growth, with two stocks rising and several others declining [1] - Among the stocks in the Artemisinin concept sector, Delong Huineng reached a daily limit increase, while Baihua Pharmaceutical, Fosun Pharmaceutical, and Zhejiang Pharmaceutical saw declines of 1.91%, 1.42%, and 1.30% respectively [1] - The overall market saw a net outflow of 300 million yuan from the Artemisinin concept sector, with only one stock, Rundu Co., receiving a net inflow of 246,700 yuan, marking it as the top stock in terms of net inflow [2] Group 2 - The top-performing concept sectors today included China-Korea Free Trade Zone with an increase of 1.45%, while the worst-performing sector was the military equipment restructuring concept, which fell by 2.91% [2] - The trading volume and turnover rates for stocks in the Artemisinin concept sector varied, with Rundu Co. showing a turnover rate of 1.66% and a slight decline of 0.23%, while other stocks like Baihua Pharmaceutical and Zhejiang Pharmaceutical experienced larger declines and negative net inflows [2]